Literature DB >> 8517859

Kinetics of the inhibition of tumour growth in mice by eicosapentaenoic acid-reversal by linoleic acid.

E A Hudson1, S A Beck, M J Tisdale.   

Abstract

Oral administration of eicosapentaenoic acid (EPA) (2.0 g/kg) by gavage to female NMRI mice bearing the MAC16 colon adenocarcinoma and with weight loss, prevented further loss in body weight and produced a delay in the growth of the tumour. Cell production and loss were determined by the [125I]5-iodo-2'-deoxyuridine method during the stationary and growth phase of the tumour in animals treated with EPA. Tumour stasis appeared to arise from an increase in the rate of cell loss from 38 to 71% without a significant change in the potential doubling time. During the subsequent growth phase the cell loss factor was reduced to 52% and this was combined with a reduced potential doubling time from 32 to 26 hr. The antiproliferative, but not the anticachectic effect of EPA could be reversed by oral administration of pure linoleic acid (LA), (1.9 g/kg) which acted to increase tumour growth by reducing the cell loss factor to 45%. Despite this reversal, incorporation of EPA into tumour cell lipids was not significantly different in animals administered with either EPA alone or combined with LA. This suggests that the antiproliferative effect of EPA in this system may arise from an indirect effect through the blocking of the catabolic effect of the tumour on host adipose tissue, which normally supplies fatty acids essential for tumour growth. This suggests that LA may be required by some tumours to prevent cell loss and that the catabolism of adipose tissue, which accompanies cancer cachexia effectively supplies this fatty acid to the tumour.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8517859     DOI: 10.1016/0006-2952(93)90188-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Enrichment of eggs with n-3 polyunsaturated fatty acids: effects of vitamin E supplementation.

Authors:  T Grune; K Krämer; P P Hoppe; W Siems
Journal:  Lipids       Date:  2001-08       Impact factor: 1.880

Review 2.  Anti-cancer activities of ω-6 polyunsaturated fatty acids.

Authors:  Yi Xu; Steven Y Qian
Journal:  Biomed J       Date:  2014 May-Jun       Impact factor: 4.910

3.  Incorporation of long-chain n-3 fatty acids in tissues and enhanced bone marrow cellularity with docosahexaenoic acid feeding in post-weanling Fischer 344 rats.

Authors:  T G Atkinson; H J Barker; K A Meckling-Gill
Journal:  Lipids       Date:  1997-03       Impact factor: 1.880

4.  Dietary menhaden oil enhances mitomycin C antitumor activity toward human mammary carcinoma MX-1.

Authors:  Y Shao; L Pardini; R S Pardini
Journal:  Lipids       Date:  1995-11       Impact factor: 1.880

5.  Key roles for GRB2-associated-binding protein 1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin E2 and transforming growth factor alpha in linoleic acid-induced upregulation of lung and breast cancer cell growth.

Authors:  M Mouradian; K D Kikawa; E D Johnson; K L Beck; R S Pardini
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2013-12-11       Impact factor: 4.006

6.  Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia.

Authors:  P M Sanders; S T Russell; M J Tisdale
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

7.  Metabolism and pharmacokinetics of the anti-tumour agent 2,3,5-trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone (CV-6504).

Authors:  H J Hussey; M J Tisdale
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

8.  Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines.

Authors:  J S Falconer; J A Ross; K C Fearon; R A Hawkins; M G O'Riordain; D C Carter
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

9.  Effect of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo.

Authors:  H J Hussey; M J Tisdale
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

10.  Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC).

Authors:  H J Hussey; M C Bibby; M J Tisdale
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.